CNS Clinical Trials in Paris

8 recruitingParis, France

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche42 enrolled33 locationsNCT04774718
Recruiting
Phase 1Phase 2

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

GliomaCNS Tumor, AdultCNS Tumor, Childhood
Centre Leon Berard70 enrolled11 locationsNCT07243470
Recruiting
Phase 2

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Primary CNS Lymphoma (PCNSL)
The Lymphoma Academic Research Organisation60 enrolled13 locationsNCT06931652
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Not Applicable

A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

CNS Metastases
Jules Bordet Institute600 enrolled17 locationsNCT04109131
Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Germ Cell TumorGliomaEpendymoma+10 more
European Organisation for Research and Treatment of Cancer - EORTC1,650 enrolled42 locationsNCT05259605
Recruiting
Phase 1Phase 2

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

LymphomaMetastatic Solid TumorsLocally Advanced Solid Tumors+1 more
Turning Point Therapeutics, Inc.75 enrolled68 locationsNCT04094610
Recruiting
Phase 1Phase 2

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

Solid TumorCNS Tumor
University Hospital Heidelberg91 enrolled14 locationsNCT03838042